UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0058
Expires: September 30, 2028
Estimated average burden
hours per response .....……..2.50

SEC FILE NUMBER

CUSIP NUMBER

FORM 12b-25

NOTIFICATION OF LATE FILING

(Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR

For Period Ended: September 30, 2026
☐ Transition Report on Form 10-K
☐ Transition Report on Form 20-F
☐ Transition Report on Form 11-K
☐ Transition Report on Form 10-Q

For the Transition Period Ended: _____

Read Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing in this Form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I — REGISTRANT INFORMATION

Niki BioSolutions, Inc.
Full Name of Registrant

Aptorum Group Limited
Former Name if Applicable

116 Village Boulevard, Suite 200
Address of Principal Executive Office (Street and Number)

Princeton, NJ 08540
City, State and Zip Code

PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

☒

(a) The reason described in reasonable detail in Part III of this Form could not be eliminated without unreasonable effort or expense;

(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

(c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III — NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

Niki BioSolutions, Inc. (the "Company") is currently in the process of finalizing complex purchase price allocation accounting, asset valuations, and the consolidation of historical financial records across legacy entities following the corporate domestication and business combination with DiamiR Biosciences Corp. on July 20, 2026 (the "Transaction") and therefore there is a delay in the filing of its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026 (the "Form 10-Q"). Due to the ongoing nature of these accounting evaluations and the required review by the Registrant's independent registered public accounting firm, a reasonable quantitative estimate of the changes in revenue, operating expenses, and net loss cannot be made at this time without unreasonable effort or expense. The Company expects to provide full financial results in the Form 10-Q, which will be filed on or before the fifth calendar day following the prescribed due date.

PART IV — OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

Thomas Freeburg	908	366-9509
(Name)	(Area Code)	(Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ☒ Yes ☐ No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☒ Yes ☐ No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

The Registrant anticipates that there will be a significant change in its results of operations for the three and nine months ended September 30, 2026, as compared to the corresponding periods of the prior fiscal year ended September 30, 2025.

These anticipated changes are primarily attributable to the completion of the Transaction. As a result of the Transaction, the Registrant's financial statements for the third quarter of 2026 will reflect the consolidated operations, expanded research and development pipelines, and administrative expenses of the combined entity, as well as significant non-recurring transaction, legal, and accounting costs associated with closing and integrating the business combination.

Niki BioSolutions, Inc.
(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date November 17, 2026 By Thomas Freeburg, CFO